Современный взгляд на лечение болезни Шегрена
- Авторы: Торгашина А.В1
-
Учреждения:
- Научно-исследовательский институт ревматологии им. В.А. Насоновой
- Выпуск: Том 27, № 13 (2020)
- Страницы: 126-131
- Раздел: Статьи
- URL: https://journals.eco-vector.com/2073-4034/article/view/312986
- DOI: https://doi.org/10.18565/pharmateca.2020.13.126-131
- ID: 312986
Цитировать
Полный текст
![Открытый доступ](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Аннотация
В статье рассматриваются особенности патогенеза болезни Шегрена и современные терапевтические подходы. Подробно обсуждается доказательная база как синтетических иммуносупрессоров, так и современных генно-инженерных биологических препаратов. Проанализированы возможные причины недостаточной доказательной базы, а также сложности при организации рандомизированных контролируемых исследований при болезни Шегрена.
Ключевые слова
Полный текст
![Доступ закрыт](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Об авторах
А. В Торгашина
Научно-исследовательский институт ревматологии им. В.А. Насоновой
Email: anna.torgashina@gmail.com
Список литературы
- Goules A.V., Tziofas A.G: Primary Sjogren's syndrome: Clinical phenotypes, outcome and the development of biomarkers. Autoimmun Rev. 2016;15:695-703. doi: 10.1007/s12026-016-8844-4.
- Barbosa E.C., Jessica Bruna Correa Lindoso, de Oliveira Conde N.C., et al. Oral manifestations and histopathology of minor salivary gland from patients with Sjogren's Syndrome and its diagnosis in a public health system. Rev Bras Odontol. 201673(4):297-304. doi: 10.18363/rbo. v73n4.p.297.
- Bordal O, Norheim K.B., R0dahl E, et al. Primary Sjogren's syndrome and the eye. Surv Ophthalmol. 2020;65(2): 119-32. Doi: 10.1016/j. survophthal.2019.10.004.
- Goules A.V, Kapsogeorgou E.K., Tziofas A.G. Insight into pathogenesis of Sjogren's syndrome: Dissection on autoimmune infiltrates and epithelial cells. Clin Immunol. 2017;182:30-40. doi: 10.1016/j.clim.2017.03.007.
- Katsiougiannis S., Tenta R., Skopouli F.N. Autoimmune epithelitis (Sjogren's syndrome); the impact of metabolic status of glandular epithelial cells on auto-immunogenicity. J Autoimmun. 2019;104:102335. Doi:10.1016/j. jaut.2019.102335.
- Skopouli F.N, Dafni U., loannidis J.P, Moutsopoulos H.M. Clinical evolution, and morbidity and mortality of primary Sjogren's syndrome. Semin Arthr Rheum. 2000;29:296-304. doi: 10.1016/ s0049-0 1 72(00)80016-5.
- Btochowiak K., Sokalski J. Labial salivary gland biopsy in the diagnosis of Sjogren's syndrome. Eur J Clin Exp Med. 2019;17(2):162-68. doi: 10.15584/ejcem.2019.2.10.
- Argyropoulou O.D., Pezoulas V., Chatzis L., et al. Cryoglobulinemic vasculitis in primary Sjogren's Syndrome: Clinical presentation, association with lymphoma and comparison with Hepatitis C-related disease. Semin Arthr Rheum. 2020;50(5):846-53. doi: 10.1016/j.semarthrit.2020.07.013.
- Sun R., Medeiros L.J., Young K.H. Diagnostic and predictive biomarkers for lymphoma diagnosis and treatment in the era of precision medicine. Mod Pathol. 2016;29(10):1118-42. Doi: 10.1038/ modpathol.2016.92.
- Ioannidis J.P, Vassiliou V.A., Moutsopoulos H.M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjogren's syndrome. Arthr Rheum. 2002;46:741-47. doi: 10.1002/art.10221.
- Lverenz D.L., St. Clair E.W. Recent advances in the search for a targeted immunomodulatory therapy for primary Sjogren's syndrome [version 1; peer review: 2 approved] F1000. Res. 2019, 8. (F1000 Faculty Rev.):1532. doi: 10.12688/ f1000reseatch.19842.1.
- Сафонова Т.Н., Васильев В.И., Лихванцева В.Г. Синдром Шегрена: Руководство для врачей. Под ред. В.Г. Лихванцевой. М., 2013. 600 с.
- Torgashina A., Rodionova E., Safonova T., et al. Efficacy of prolonged maintenance monotherapy with rituximab in patients with primary Sjogren's syndrome: three-year follow-up. Ann Rheum Dis. 2018;77(Suppl. 2). doi: 10.1136/annrheumdis-2018-eular.5718.
- Cankaya H., Alpoz E., Karabulut G., et al. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjogren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol. Oral Radiol. Endod. 2010;110:62-7. Doi: 10.1016/j. tripleo.2010.02.032.
- Tishler M., Yaron I., Shirazi I., Yaron M. Hydroxychloroquine treatment for primary Sjogren's syndrome: its effect on salivary and serum inflammatory markers. Ann Rheum Dis. 1999;58:253-56. doi: 10.1136/ard.58.4.253.
- Kruize A., Hene R., Kallenberg C., et al. Hydroxychloroquine treatment for primary Sjogren's syndrome: a two year double blind cross over trial. Ann Rheum Dis. 1993;52:360-4. doi: 10.1136/ard.52.5.360.
- Gottenberg J.-E, Ravaud P, Puechal X., et al. Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome the JOQUER randomized clinical trial. JAMA. 2014;312:249-58. Doi: 10.1001/ jama.2014.7682.
- Romro V.C, Talarico R., Scir C.A., et al. Sjogren's syndrome: state of the art on clinical practice guidelines. RMD. Open. 2018;0:e000789. doi: 10.1136/rmdopen-2018-000789.
- Price E.J., Rauz S., Tappuni A.R., et al. The British Society for Rheumatology guideline for the management of adults with primary Sjogren’s Syndrome. Rheumatol. (Oxford). 2017;56(10):e24-48. Doi: 10.1093/ rheumatology/kex166.
- Rogers S., Williams C., Roman G. Myelopathy in Sjogren’s syndrome: role of non-steroidal immunosuppressants. Drugs. 2004;64:123-32. doi: 10.2165/00003495-200464020-00001.
- Misterska-Skora M., Sebastian A., Dziefiel P., Sebastian M, Wiland P. Inclusion body myositis associated with Sjogren's syndrome. Rheumatol Int. 2013;33:3083-86. doi: 10.1007/s00296-012-2556-4.
- Skopouli F., Jagiello P., Moutsopoulos H. Methotrexate in primary Sjogren's syndrome. Clin Exp Rheumatol. 1996;14:555-58.
- Hwang J., Yang T., Lee J., et al. Severe pulmonary hypertension in primary Sjogren's syndrome. Korean Circ J. 2013;43(7):504. Doi:10.4070/ kcj.2013.43.7.504.
- Darrieutort-Laffite C., Andre V., Hayem G., et al. Sjogren's syndrome complicated by interstitial cystitis: a case series and literature review. J Bone Spine. 2015;82:245-50. doi: 10.1016/j.jbspin. 2014.12.007.
- Deheinzelin D., Capelozzi V.L., Kairalla R.A., et al. Interstitial lung disease in primary Sjogren's syndrome. Clinical-pathological evaluation and response to treatment. Am J Respir Crit Care Med. 1996;154:794-99. Doi: 10.1164/ ajrccm.154.3.8810621.
- Kaufman I., Schwartz D., Caspi D., Paran D. Sjogren's syndrome - not just Sicca: renal involvement in Sjogren's syndrome. Scand J Rheumatol. 2008;37:213-18. doi: 10.1080/03 009 740 701867323.
- Hermisson M, Klein R., Schmidt F., Weller M., Kuker W. Myelopathy in primary Sjogren's syndrome: diagnostic and therapeutic aspects. Acta Neurol Scand. 2002. doi: 10.1034/j.1600-0404.2002.01167.x.
- Yeoman C., Franklin C. The treatment of Sjogren's disease in NZB/NZW F1 hybrid mice with azathioprine: a two-stage study. Clin Exp Rheumatol. 1994;12:49-53.
- Price E, Rigby S., Clancy U, Venables PA. Double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren’s syndrome. J Rheumatol. 1998;25:896-99.
- Drosos A., Skopouli F., Galanopoulo V., et al. Cyclosporin A. Therapy in patients with primary Sjogren's syndrome: results at one year. Scan J Rheumatol. 1986;61(Suppl.):246-49.
- Sall K., Stevenson O., Mundorf T., Reis B. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophtalmic emulsion in moderate to severe dry eye disease. Ophtalmol. 2005;112:1790-94. doi: 10.1016/s0161-6420(99)00176-1.
- Van Woerkom J.M.Kruize A.A., Geenen R., et al. Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot study. Ann Rheum Dis. 2007;66:1026-32. Doi: 10.1136/ ard.2006.060905.
- Bikker A., van Woerkom J.-M, Kruize A.A., et al. Clinical efficacy of leflunomide in primary Sjogren's syndrome is associated with regulation of T-cell activity and upregulation of IL-7 receptor α expression. Ann Rheum Dis. 2012;71:1934-41. doi: 10.1136/annrheumdis-2011-201026.
- Fox PC., Datiles M, Atkinson J.C., et al. Prednisone and piroxicam for treatment of primary Sjogren's syndrome. Clin Exp Rheumatol. 1993;11:149-56.
- Miyawaki S., Nishiyama S., Matoba K. Efficacy of low-dose prednisolone maintenance for saliva production and serological abnormalities in patients with primary Sjogren’s syndrome. Intern Med. 1999;38:938-43. doi: 10.2169/ internalmedicine.38.938.
- Carsons S.E., Vivino F.B., Parke A., et al. Treatment Guidelines for Rheumatologic Manifestations of Sjogren’s Syndrome: Use of Biologic Agents, Management of Fatigue, and Inflammatory Musculoskeletal Pain. Arthr Care Res. (Hoboken). 2017;69(4):517-27. doi: 10.1002/acr.22968.
- Blvarez-Rivasa N., Sang-Parkb H., del Campoc PD., et al. Efficacy of Belimumab in Primary Sjogren's Syndrome: A Systematic Review. Reumatol Clin. 2020;22;S1699-258X(20)30076-0. doi: 10.1016/j.reuma.2020.03.003.
- Mavragani C.P, Moutsopoulos H.M. Sjogren’s syndrome: Old and new therapeutic targets. J Autoimmun. 2020;110:102364. Doi:10.1016/j. jaut.2019.102364.
- Gottenberg J.E., Cinquetti G., Larroche C., et al. Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry. Ann Rheum Dis. 2013;72(6):1026-31. doi: 10.1136/annrheumdis-2012-202293.
- Dass S., Bowman S.J., Vital E.M., et al. Reduction of fatigue in Sjo'gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. Ann Rheum Dis. 2008;67:1541-44. doi: 10.1136/ard.2007.083865.
- Meijer J.M., Meiners PM., Vissink A., et al. Effectiveness of Rituximab Treatment in Primary Sjogren's Syndrome. A Randomized, DoubleBlind, Placebo-Controlled Trial. Arthr Rheum. 2010;62(4):960-68. doi: 10.1002/art.27314.
- Devauchelle-Pensec V., Mariette X., Jousse-Joulin S., et al. Treatment of Primary Sjo'gren Syndrome With Rituximab. A Randomized Trial. Ann Intern Med. 2014;160:233-42. doi: 10.7326/M13-1085.
- Bowman S.J., Everett C.C., O’Dwyer J.L., et al. Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjogren's syndrome. Arthr Rheum. 2017;69(7):1440-50. Doi: 10.1002/ art.40093.
- Adatia F.A., Michaeli-Cohen A., Naor J., et al. Correlation between corneal sensitivity, subjective dry eye symptoms and corneal staining in Sjogren's syndrome. Canadian journal of ophthalmology. J Canad d'ophtalmol. 2004;39(7):767-71. doi: 10.1016/s0008-4182(04)80071-1.
- Aure M.H., Arany S., Ovitt C.E. Salivary Glands: Stem Cells, Self-duplication, or Both? J Dent Res. 2015;94(11):1502-507. doi: 10.1177/0022034515599770.
Дополнительные файлы
![](/img/style/loading.gif)